Cite
HARVARD Citation
Laribi, K. et al. (n.d.). The bendamustine plus rituximab regimen is active against primary nodal marginal zone B‐cell lymphoma. Hematological oncology. 35 (4), pp. 536-541. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Laribi, K. et al. (n.d.). The bendamustine plus rituximab regimen is active against primary nodal marginal zone B‐cell lymphoma. Hematological oncology. 35 (4), pp. 536-541. [Online].